We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen Gets EU Nod to Add Survival Data on Blincyto's Label
Read MoreHide Full Article
Biotech major Amgen Inc. (AMGN - Free Report) announced that it has received European Commission’s (EC) approval to include overall survival (OS) data from the TOWER study on the label of its BiTE antibody, Blincyto.
Blincyto is approved for treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The TOWER study was conducted to support the conversion of Blincyto's accelerated approval to full approval. The study evaluated the efficacy of Blincyto versus standard of care (SOC) chemotherapy for the treatment of Ph- relapsed or refractory B-cell precursor ALL in adults.
Results from a late-stage study showed that median overall survival for patients on Blincyto was 7.7 months compared with 4 months for standard of care (SOC) chemotherapy.
Blincyto’s label in the United States already includes OS data from the TOWER study following the approval received from the FDA in July last year. In fact, the inclusion of the OS data has been instrumental in driving sales of the drug higher in the past two quarters. Blincyto sales surged 44% from the year-ago period to $49 million in the first quarter of 2018, reflecting a rise in demand
The inclusion of the OS data on the European label of the drug should further boost sales.
We remind investors that Pfizer Inc.’s (PFE - Free Report) Besponsa was approved for the treatment of relapsed or refractory B-cell precursor ALL in June last year in the EU, increasing competition for Blincyto.
Amgen’s shares have gained 5.8% so far this year against a 7.2% decrease registered by the industry.
Amgen currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include CRISPR Therapeutics AG (CRSP - Free Report) and Genomic Health Inc , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
CRISPR Therapeutics’ loss per share estimates narrowed 7.8% for 2018 and 9% for 2019 in the last 60 days. The stock has skyrocketed 166.7% year to date.
Genomic Health’s earnings estimates surged almost 47% for 2018 and 5.6% for 2019 in the past 60 days. The stock has soared 45.5% so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Amgen Gets EU Nod to Add Survival Data on Blincyto's Label
Biotech major Amgen Inc. (AMGN - Free Report) announced that it has received European Commission’s (EC) approval to include overall survival (OS) data from the TOWER study on the label of its BiTE antibody, Blincyto.
Blincyto is approved for treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The TOWER study was conducted to support the conversion of Blincyto's accelerated approval to full approval. The study evaluated the efficacy of Blincyto versus standard of care (SOC) chemotherapy for the treatment of Ph- relapsed or refractory B-cell precursor ALL in adults.
Results from a late-stage study showed that median overall survival for patients on Blincyto was 7.7 months compared with 4 months for standard of care (SOC) chemotherapy.
Blincyto’s label in the United States already includes OS data from the TOWER study following the approval received from the FDA in July last year. In fact, the inclusion of the OS data has been instrumental in driving sales of the drug higher in the past two quarters. Blincyto sales surged 44% from the year-ago period to $49 million in the first quarter of 2018, reflecting a rise in demand
The inclusion of the OS data on the European label of the drug should further boost sales.
We remind investors that Pfizer Inc.’s (PFE - Free Report) Besponsa was approved for the treatment of relapsed or refractory B-cell precursor ALL in June last year in the EU, increasing competition for Blincyto.
Amgen’s shares have gained 5.8% so far this year against a 7.2% decrease registered by the industry.
Amgen currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include CRISPR Therapeutics AG (CRSP - Free Report) and Genomic Health Inc , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
CRISPR Therapeutics’ loss per share estimates narrowed 7.8% for 2018 and 9% for 2019 in the last 60 days. The stock has skyrocketed 166.7% year to date.
Genomic Health’s earnings estimates surged almost 47% for 2018 and 5.6% for 2019 in the past 60 days. The stock has soared 45.5% so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>